Research and Development in Biotechnology - Companies & Stock Screener

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

YoY Change

CSL Ltd. - ADR

CSLLY

Market Cap $83.68B

Dividends 3.5%

P/E Ratio 28.7

Revenue $8.3B +1.1%

Net Income $402M -80.0%

Profit Margin +4.8%

View Stock

Exact Sciences Corp.

EXAS

Market Cap $20.03B

Dividends 0.0%

P/E Ratio -95.7

Revenue $878M +23.1%

Net Income -$86M -90.1%

Profit Margin -9.8%

View Stock

Genmab - ADR

GMAB

Market Cap $17.8B

Dividends 0.0%

P/E Ratio 21.5

Revenue $899M +25.8%

Net Income $53.2M -72.7%

Profit Margin +5.9%

View Stock

Medpace Holdings Inc

MEDP

Market Cap $15.37B

Dividends 0.0%

P/E Ratio 33.1

Revenue $707M +26.5%

Net Income $124M +8.1%

Profit Margin +17.5%

View Stock

Exelixis Inc

EXEL

Market Cap $14.2B

Dividends 0.0%

P/E Ratio 18.1

Revenue $611M +10.0%

Net Income $210M +31.9%

Profit Margin +34.5%

View Stock

Icon Plc

ICLR

Market Cap $12.84B

Dividends 0.0%

P/E Ratio 29.6

Revenue $2.03B +1.6%

Net Income $105M -32.0%

Profit Margin +5.2%

View Stock

Charles River Laboratories International Inc.

CRL

Market Cap $11.24B

Dividends 0.0%

P/E Ratio -62.2

Revenue $996M +1.2%

Net Income -$14.8M -158.3%

Profit Margin -1.5%

Employees 17K

View Stock

Abivax - ADR

ABVX

Market Cap $10.27B

Dividends 0.0%

P/E Ratio -25.4

Revenue -$2.02M -200.7%

Net Income -$222M +369.4%

Profit Margin +11009.1%

View Stock

Nuvalent Inc - Ordinary Shares - Class A

NUVL

Market Cap $9.11B

Dividends 0.0%

P/E Ratio -20.4

Revenue $0.00

Net Income -$109M +29.2%

Profit Margin

Employees 2.02K

View Stock

Crinetics Pharmaceuticals Inc

CRNX

Market Cap $8.85B

Dividends 0.0%

P/E Ratio -16.3

Revenue $10.7M +2873.4%

Net Income -$128M +32.1%

Profit Margin -1191.0%

View Stock

Immunovant Inc

IMVT

Market Cap $8.15B

Dividends 0.0%

P/E Ratio -14.3

Revenue $0.00 -100.0%

Net Income -$148M +38.9%

Profit Margin

View Stock

Scholar Rock Holding Corp

SRRK

Market Cap $6.8B

Dividends 0.0%

P/E Ratio -16.4

Revenue $0.00

Net Income -$106M +41.2%

Profit Margin

View Stock

Mirum Pharmaceuticals Inc

MIRM

Market Cap $6.13B

Dividends 0.0%

P/E Ratio -9.0

Revenue $0.00 -100.0%

Net Income -$790M +5283.6%

Profit Margin

View Stock

Erasca Inc

ERAS

Market Cap $5.76B

Dividends 0.0%

P/E Ratio -19.9

Revenue $0.00

Net Income -$183M +492.4%

Profit Margin

Employees 2.02K

View Stock

IDYA

Market Cap $3.52B

Dividends 0.0%

P/E Ratio -23.4

Revenue $6.56M

Net Income -$98.5M +38.0%

Profit Margin -1502.1%

View Stock